PDRN for Lichen Sclerosus: The Regenerative Treatment Most Patients Have Never Heard Of

March 26, 2026

By

Alex Force

PDRN has published clinical data in lichen sclerosus and addresses exactly what steroids cannot: tissue depletion, poor vascularization, and slow healing that persist even when inflammation is controlled. Here is what the research actually shows.

PDRN polydeoxyribonucleotide injectable treatment for lichen sclerosus tissue regeneration

Most people with lichen sclerosus have been told some version of the same thing: use your steroid, protect the skin, manage triggers, and accept that this is a lifelong condition with no cure.

That framework is not wrong. But it is incomplete in one specific and important way.

Steroids are excellent at controlling the immune inflammation that drives LS. What they do not do is rebuild atrophic tissue, restore vascular supply to depleted epithelium, or support the regenerative processes that fragile LS tissue desperately needs between flares. For many patients, inflammation is reasonably controlled but the tissue itself remains thin, slow to heal, prone to fissuring, and structurally depleted in ways that standard management does not address.

This is the biological gap that PDRN, polydeoxyribonucleotide, is designed to fill. It has published clinical data specifically in lichen sclerosus. It has a coherent mechanism. It has an excellent safety profile. And the overwhelming majority of LS patients have never been told it exists.

This article covers what it is, what the research actually shows, and who is most likely to benefit from it.

What PDRN Actually Is

PDRN stands for polydeoxyribonucleotide. It is a biologically active compound made from purified DNA fragments extracted from the sperm cells of salmon trout. The molecular weight of these fragments ranges from 50 to 1,500 kilodaltons, and this specific molecular weight range determines PDRN's biological activity and distinguishes it from other DNA-derived compounds.

Because PDRN consists of purified DNA fragments without proteins or peptides, it has very low immunogenicity. It does not trigger immune rejection or allergic responses. This gives it an excellent safety profile across a wide range of tissues including genital mucosa, which matters enormously for LS patients.

The commercial injectable product used in clinical studies is Placentex injectable solution, manufactured by Mastelli S.r.l. in Sanremo, Italy. It is a registered pharmaceutical drug available in injectable vials (5.625mg/3ml for intradermal and subdermal use). The injectable form requires medical administration by a clinician. Mastelli also produces a topical gel product under the name Turnover, but this is a separate product entirely and is not what the clinical LS studies used. Throughout this article, when we say Placentex we mean specifically the injectable solution, not any topical cream or gel product.

How PDRN Works in Tissue and Why It Makes Sense for LS

The adenosine A2A receptor mechanism

When PDRN is administered by injection, nuclease enzymes in the plasma and tissue break down its DNA chains and release adenosine. That adenosine binds to adenosine A2A receptors on local cells, triggering a cascade of biological effects that are directly relevant to the specific problems LS tissue develops over time.

The most important downstream effects are upregulation of VEGF, which drives new blood vessel formation, stimulation of fibroblast proliferation and activity, and reduction of pro inflammatory cytokines including TNF-α and IL-1β. We know A2A receptor binding is the actual mechanism because a selective A2A antagonist called DMPX abolishes PDRN's effects completely.

Why does this matter for LS? Atrophic LS tissue is often poorly vascularized. The white, thin, depleted appearance of established LS reflects structural changes that go beyond inflammation alone. Poor blood supply means poor oxygenation, poor nutrient delivery, and poor capacity for tissue repair. PDRN injectable solution addresses this at the vascular level through VEGF upregulation, which is something no existing first line LS treatment does.

The salvage pathway mechanism

A secondary mechanism is direct nucleotide provision. PDRN fragments enter the cell's DNA salvage pathway, providing ready made building blocks for DNA synthesis and cellular repair without the energy cost of building them from scratch. In tissue under chronic stress, as LS epithelium certainly is, this metabolic support may facilitate more efficient cellular repair and turnover at a baseline level.

The biological profile that fits PDRN to LS

From our phase based treatment framework: PDRN scores 9/10 on repair potential, 6/10 on anti fibrotic potential, 6/10 on inflammation control, 7/10 on mucosa safety, and 7/10 on evidence strength.

This profile tells you something important. PDRN is a repair biased molecule. Its strongest argument is for tissue that is regeneration poor, thin, atrophic, and slow to heal, not for tissue dominated by active cytokine driven flare. The best phases are Phase 2, the closing and fragile transition phase, and Phase 3, the fibrotic and atrophic phase where structural depletion is the dominant problem.

For more on how these phases work and how to identify which one you are in, see [Steroids and Treatment Logic in Lichen Sclerosus: A Complete Guide] and [Is Lichen Sclerosus Progressive? What Progression Really Means].

What the Research in Lichen Sclerosus Actually Shows

The evidence base is not large. That matters and will be stated clearly in the limitations section. But what exists is consistent in direction, mechanistically coherent, and from independent research groups working in urology and dermatology settings in Italy, where injectable Placentex has been available and studied for longer than in most other countries.

Laino 2012 — the first clinical observation

The first published report of PDRN in LS appeared in the European Journal of Dermatology in 2012. Laino documented adjuvant clinical effects when injectable PDRN was combined with standard corticosteroid treatment, including improvements in inflammation, atrophy, leukoplakia, and pigmentation, with long standing remissions after eight injection sessions. This was a brief initial observation but it established the proof of concept that PDRN injection adds benefit beyond what steroids achieve alone.

Laino 2013 — controlled comparison in male genital LS

The most methodologically detailed study was published in Dermatology Research and Practice in 2013, with full text available at PMC3893745.

28 male patients aged 25 to 65 with genital lichen sclerosus were divided into two groups. Group A received intradermal Placentex injectable solution (5.625mg/3ml) combined with clobetasol propionate 0.05% cream. Group B received clobetasol alone. Both groups were assessed using the Investigator's Global Assessment and the Dermatology Life Quality Index.

Group A showed regression of most clinical pathological signs. Photographic documentation showed in some cases complete resolution of ecchymotic areas of the glans, complete resolution of lichenoid inflammatory areas and preputial fissures, and significant improvement in sclerotic preputial rings with partial repigmentation. Group B showed only moderate improvement. No adverse events were recorded in either group.

The conclusion was direct: intradermal Placentex injectable combined with clobetasol was associated with clearly better clinical improvement than clobetasol in single therapy.

Zucchi et al. 2016 — 21 patients including diabetics and hypertensives

Zucchi, Cai, Cavallini and colleagues published a prospective pilot study in Urologia Internationalis evaluating PDRN locoregional injection therapy in 21 male patients with genital LS. This study is particularly significant because it included diabetic and hypertensive patients, populations for whom intensive steroid use creates real metabolic concerns.

All patients received weekly injectable PDRN sessions for two cycles of ten sessions. DLQI scores dropped from an average of 15 to 4, which is a statistically highly significant improvement (p<0.0001). 80% of patients considered their post treatment condition improved on the Patient Global Impression of Improvement questionnaire. Tissue trophism, skin elasticity, and irritative symptoms all improved. Tolerability was excellent throughout.

Sexual function scores did not show statistically significant change, which the authors attributed to the structural nature of some sexual dysfunction in established LS rather than a limitation of PDRN itself.

Arena and Romeo 2016 — the pediatric LS angle

The commentary from Arena and Romeo at the University of Messina's Paediatric Surgery unit adds a clinical dimension that is easy to overlook. At their unit, approximately 45% of pediatric patients undergoing circumcision for secondary phimosis were found to have LS, confirming the underrecognized prevalence of pediatric LS in phimosis cases. The authors note that steroids carry side effects and are sometimes contraindicated even in children, particularly with diabetes, and propose injectable PDRN as a potentially important alternative approach. They also raise the question of whether a topical PDRN formulation could be explored for pediatric patients where needle administration is impractical, though they are clear that the clinical evidence exists for the injectable form only.

What systematic reviews conclude

Multiple systematic reviews and pharmacological overviews have now included the PDRN LS data. The Frontiers in Pharmacology review by Squadrito and colleagues states that Placentex injectable subdermal injections combined with daily topical corticosteroids resulted in marked reduction of most clinical signs. The 2024 systematic review of treatment modalities for genital LS explicitly identifies PDRN injection as one of the adjunct therapies that has proven to improve patient outcomes and can be used in conjunction with high potency topical corticosteroids. The narrative dermatology review in the Journal of Cutaneous and Aesthetic Surgery notes long standing remissions in LS after intradermal PDRN injection combined with topical steroids.

The direction of findings across independent sources is consistent. This is not a single group's positive result. Multiple reviewers synthesizing the evidence reach the same conclusion.

PDRN versus Steroids: Understanding What Each One Does

What steroids do and what they leave undone

Topical corticosteroids, clobetasol, mometasone, hydrocortisone, suppress the Th1 immune activation that drives LS. They reduce IFN-γ, TNF-α, and IL-1β signaling, interrupt NF-κB amplification, and calm mast cell activity. This is why they work and why they are irreplaceable for active immune flares.

What steroids do not do is rebuild atrophic tissue. They do not improve vascular supply to depleted epithelium. They do not drive fibroblast regenerative activity or support epithelial turnover in chronically thinned tissue. Long-term steroid use can even contribute to tissue thinning in some contexts, which is one of the legitimate concerns around high potency maintenance.

For more on how steroids work in LS and when each potency is appropriate, see [How to Use Clobetasol Correctly for Lichen Sclerosus] and [Steroid Maintenance vs Overuse in Lichen Sclerosus].

What PDRN injectable adds that steroids cannot

PDRN injection addresses the regenerative deficit that steroids leave untreated. When LS tissue has been chronically inflamed and structurally depleted, controlling the immune component does not automatically restore what has been lost at the tissue architecture level. PDRN's A2A-mediated VEGF upregulation, fibroblast stimulation, and nucleotide provision address this regenerative gap directly.

The clinical data consistently shows injectable PDRN working best as an adjuvant to steroids rather than as a replacement for them. The biological logic fully supports this. You need immune control and tissue regeneration as complementary targets. They are not competing approaches. They address different biological problems in the same tissue.

The patient profile that benefits most from PDRN injection

Inflammation is adequately controlled by the existing steroid protocol but tissue quality remains poor, thin, fragile, and persistently symptomatic at a level below active flare.

Fissures that recur in the same locations and close slowly or incompletely despite good inflammation management.

Significantly atrophic tissue with signs of poor local vascularization, the plaques that feel cold or stiff, white from structural depletion rather than active inflammation.

Patients with diabetes or other conditions where intensive steroid use is metabolically problematic and a steroid-sparing regenerative approach has real clinical value.

Patients who have optimized their primary management and plateaued, where the remaining symptom burden relates to tissue quality rather than immune activity.

For more on why some patients plateau despite correct steroid use, see [Why Lichen Sclerosus Flares Come Back Even When You Are Doing Everything Right].

The Injectable Placentex Protocol: What Clinical Studies Used

Concentration and administration

The form used in all published LS clinical studies is Placentex injectable solution (5.625mg PDRN in a 3ml vial), administered intradermally or subdermally into the affected tissue by a clinician. This is not a cream, not a topical product, and not something a patient applies at home. It is a medical procedure requiring injection into genital tissue by someone with appropriate training and experience.

Different published protocols use weekly injection sessions in cycles of ten (Zucchi 2016) or eight injection sessions combined with daily topical steroid (Laino 2012/2013). No single protocol has been established as definitively optimal because the comparative data does not exist yet.

The topical formulation: what it is and what it is not

Mastelli also produces Turnover, a topical gel with a lower PDRN concentration. This is a separate product from the injectable Placentex solution and has not been studied in LS clinical trials. There is no published evidence for topical PDRN in LS specifically. The injectable form is what has clinical data.

The honest position on topical PDRN: on barrier compromised LS tissue, penetration of topical actives is higher than on normal skin because the protective stratum corneum is structurally impaired. This makes topical application biologically more plausible for LS patients than for patients with intact skin, and the tolerability profile is excellent across all PDRN research. But plausibility is not evidence. Patients interested in this area should understand that the topical form is a low risk exploratory option, not a substitute for the injectable protocol that the clinical studies support.

PDRN in Context with Other Regenerative Approaches

PDRN versus PRP

Platelet rich plasma is the other regenerative injectable approach most discussed in LS. Both target the regenerative deficit rather than the immune component. But their evidence profiles differ meaningfully. A randomized double blind placebo controlled trial of PRP in vulvar LS found no statistically significant improvement over saline placebo, which is a sobering result from a well designed study. Other PRP studies have shown improvements but with less rigorous methodology.

PDRN injection has a more consistent mechanistic basis through A2A receptor biology and a more consistent direction of findings across independent groups. The evidence base for PDRN is smaller but more directionally uniform. Neither approach has large RCT data. The preliminary signal for injectable PDRN is stronger.

PDRN versus CO2 fractional laser

Fractional CO2 laser creates controlled micro injury to stimulate collagen remodeling and tissue regeneration. It is most relevant for established fibrotic Phase 3 tissue with loss of elasticity and architectural change. Injectable PDRN targets the regenerative deficit somewhat earlier, in Phase 2 closing tissue and early Phase 3, through different biology. These are not competing approaches. In appropriate clinical settings a clinician might consider them as sequential steps: injectable PDRN during the regenerative phase, laser for established fibrosis when inflammation is fully controlled.

Laser cannot be used during active inflammatory phases. Injectable PDRN can be used during Phase 2 tissue states where laser would be contraindicated.

Where PDRN injection fits in the phase framework

During Phase 1, active immune flare, PDRN injection is not the priority. Steroid management is. PDRN does not suppress active immune inflammation adequately to be used as a primary tool here.

During Phase 2, the closing and fragile transition, injectable PDRN has its strongest biological argument. Tissue is closing but regeneration-poor. A2A-driven VEGF and fibroblast activity supports re-epithelialization and vascular repair alongside continuing steroid management.

During Phase 3, the fibrotic and atrophic phase, injectable PDRN is relevant for the atrophic end of the spectrum where tissue is thin and depleted, less so for dense established fibrosis where antifibrotic approaches are needed.

During Phase 4, remission and maintenance, repeat PDRN injection cycles may be worth considering for patients with persistently fragile baseline tissue quality even in controlled periods.

Practical Information for Patients Considering Injectable PDRN

Finding appropriate care

Intradermal PDRN injection for LS is not yet standard of care outside specialist dermatology and urology. In Italy it is most available through dermatology and urology units with LS experience. Outside Italy, access is more variable. When seeking this approach, ask specifically about the clinician's experience with injectable PDRN for LS as opposed to aesthetic rejuvenation applications. The protocols, injection depth, and tissue context are different.

What to expect realistically

The clinical data shows consistent improvement in tissue quality, symptom burden, and quality of life scores. In the Zucchi 2016 study, DLQI scores dropped from 15 to 4, which represents a major improvement in daily quality of life impact. 80% of patients considered their condition improved. These are meaningful clinical outcomes. They are not cure. They are significant, sustained improvement in a condition that is otherwise difficult to move beyond a plateau.

Response is not immediate. Regenerative tissue repair is a biological process that takes weeks to become visible. Published protocols involve multiple injection sessions over weeks to months, not single treatments.

How injectable PDRN fits alongside existing management

Injectable PDRN does not replace any component of standard LS management. Steroid protocol remains the primary immune control strategy. Barrier protection remains essential. PDRN injection is an add-on regenerative layer for patients who have optimized their primary management and have a specific tissue regeneration problem that existing tools do not address.

For more on building a complete management approach, see [Daily Care for Lichen Sclerosus: The Complete System for Stability] and [Natural Treatments for Lichen Sclerosus: What Actually Helps and What Often Makes It Worse].

What the Evidence Does Not Yet Tell Us

The published injectable PDRN LS studies are small. The largest enrolled 28 patients. None are randomized, double blind, and placebo controlled. All are from Italian research groups, meaning independent international replication is absent. The Arena and Romeo commentary explicitly calls for multicentric randomized clinical trials, and those trials have not yet been conducted.

The optimal injection protocol has not been established by comparative data. Different published protocols vary in concentration, session frequency, and total treatment duration in ways that may matter for outcome.

Long-term follow up data beyond six months is limited. Whether repeat injectable PDRN cycles are needed to maintain improvements is not yet known.

Female genital LS has less published data than male genital LS in the PDRN injection literature, though the mechanism is tissue level and not sex specific, and there is no biological reason to expect fundamentally different results.

These limitations do not make the existing evidence meaningless. They mean injectable PDRN in LS is a genuinely promising approach supported by mechanistically coherent evidence and consistent preliminary clinical findings, not yet a fully characterized treatment with established protocols and long-term data from thousands of patients.

Why This Matters for Patients Right Now

The gap that injectable PDRN addresses is real and currently underserved. Steroids manage the immune component of LS effectively when used correctly. Nothing in current standard management addresses the regenerative deficit that accumulates in tissue that has been chronically inflamed, structurally depleted, and slow to recover.

For patients who are doing everything right on the management side but whose tissue remains fragile, thin, and persistently problematic, there is a biologically coherent, clinically supported, safe option that most of them have never been offered and most clinicians outside specialist settings have not yet incorporated into their thinking.

That is the honest case for knowing about injectable PDRN. Not that it cures LS. Not that it replaces steroids. But that it addresses a biological problem that nothing else currently addresses, in a way that the preliminary evidence consistently supports, and that patients with the right profile should be aware of as an option to discuss with a specialist.

For more on what other advanced options exist and how they fit into LS management, see [Does Lichen Sclerosus Always Scar? What's Permanent vs What Isn't] and [Lichen Sclerosus and Cancer Risk: What Actually Matters].